<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00856388</url>
  </required_header>
  <id_info>
    <org_study_id>I 118807</org_study_id>
    <secondary_id>NCI-2009-01508</secondary_id>
    <nct_id>NCT00856388</nct_id>
  </id_info>
  <brief_title>Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders</brief_title>
  <official_title>A Pilot Trial Of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan, And Low Dose Total Body Irradiation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is studying how well giving fludarabine phosphate and melphalan together
      with total-body irradiation followed by donor stem cell transplant works in treating patients
      with hematologic cancer or bone marrow failure disorders. Giving low doses of chemotherapy
      and total-body irradiation before a donor peripheral blood stem cell transplant helps stop
      the growth of cancer cells or abnormal cells. It may also stop the patient's immune system
      from rejecting the donor's stem cells. The donated stem cells may replace the patient's
      immune cells and help destroy any remaining cancer or abnormal cells (graft-versus-tumor
      effect)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the transplant related mortality (TRM) of this reduced intensity
      transplantation (RIT) combination in a patient population that is usually not eligible for a
      full myeloablative allogeneic transplant.

      SECONDARY OBJECTIVES:

      I. To evaluate engraftment, safety, clinical response, evidence of graft-versus-malignancy
      effect/graft-versus-host disease (GVHD) and overall outcomes of treatment with our RIT
      regimen across a variety of hematological conditions.

      OUTLINE: Patients receive fludarabine phosphate intravenously (IV) over 30 minutes on days -5
      to -2 and melphalan* IV over 30 minutes on day -2. Patients then undergo total-body
      irradiation on day -1 and allogeneic stem cell transplantation on day 0.

      Note: *Patients with chromosomal breakage syndromes, such as Fanconi anemia or dyskeratosis
      congenita, receive anti-thymocyte globulin IV over 4 hours on day -4 to -2 instead of
      melphalan.

      After completion of study treatment, patients are followed up periodically.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 14, 2009</start_date>
  <completion_date type="Anticipated">August 15, 2019</completion_date>
  <primary_completion_date type="Actual">August 9, 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Day 100 TRM</measure>
    <time_frame>First 100 days</time_frame>
    <description>Day 100 Treatment Related Mortality An exact 95% confidence interval will be provided.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Time to ANC Engraftment</measure>
    <time_frame>Days 30</time_frame>
    <description>Median Time to ANC Engraftment
Summarized using standard descriptive statistics along with corresponding 95% confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time to Platelet Engraftment</measure>
    <time_frame>Day 100</time_frame>
    <description>Median Time to Platelet Engraftment
Summarized using standard descriptive statistics along with corresponding 95% confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Complete Donor Chimerism - Blood</measure>
    <time_frame>Day 30</time_frame>
    <description>Rate of Complete Donor Chimerism - Blood
Summarized using standard descriptive statistics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Complete Donor Chimerism - Blood</measure>
    <time_frame>Day 100</time_frame>
    <description>Rate of Complete Donor Chimerism - Blood
Summarized using standard descriptive statistics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute GVHD Grade III-IV</measure>
    <time_frame>Up to day 100</time_frame>
    <description>Acute GVHD grade III-IV
Summarized using standard descriptive statistics along with corresponding 95% confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1 yr Extenstive Chronic GVHD</measure>
    <time_frame>Up to 4.5 years</time_frame>
    <description>1 yr Extensive Chronic GVHD
Summarized using standard descriptive statistics along with corresponding 95% confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3 yr Overall Survival</measure>
    <time_frame>Up to 4.5 years</time_frame>
    <description>3 yr Overall Survival estimated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Accelerated Phase Chronic Myelogenous Leukemia</condition>
  <condition>Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome</condition>
  <condition>Adult Acute Lymphoblastic Leukemia in Remission</condition>
  <condition>Adult Acute Myeloid Leukemia in Remission</condition>
  <condition>Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities</condition>
  <condition>Adult Acute Myeloid Leukemia With Del(5q)</condition>
  <condition>Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)</condition>
  <condition>Adult Nasal Type Extranodal NK/T-cell Lymphoma</condition>
  <condition>Anaplastic Large Cell Lymphoma</condition>
  <condition>Angioimmunoblastic T-cell Lymphoma</condition>
  <condition>Aplastic Anemia</condition>
  <condition>Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative</condition>
  <condition>Childhood Acute Lymphoblastic Leukemia in Remission</condition>
  <condition>Childhood Acute Myeloid Leukemia in Remission</condition>
  <condition>Childhood Chronic Myelogenous Leukemia</condition>
  <condition>Childhood Diffuse Large Cell Lymphoma</condition>
  <condition>Childhood Immunoblastic Large Cell Lymphoma</condition>
  <condition>Childhood Myelodysplastic Syndromes</condition>
  <condition>Childhood Nasal Type Extranodal NK/T-cell Lymphoma</condition>
  <condition>Chronic Eosinophilic Leukemia</condition>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <condition>Chronic Neutrophilic Leukemia</condition>
  <condition>Chronic Phase Chronic Myelogenous Leukemia</condition>
  <condition>de Novo Myelodysplastic Syndromes</condition>
  <condition>Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue</condition>
  <condition>Fanconi Anemia</condition>
  <condition>Juvenile Myelomonocytic Leukemia</condition>
  <condition>Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable</condition>
  <condition>Nodal Marginal Zone B-cell Lymphoma</condition>
  <condition>Noncontiguous Stage II Adult Burkitt Lymphoma</condition>
  <condition>Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma</condition>
  <condition>Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma</condition>
  <condition>Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma</condition>
  <condition>Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma</condition>
  <condition>Noncontiguous Stage II Adult Lymphoblastic Lymphoma</condition>
  <condition>Noncontiguous Stage II Grade 1 Follicular Lymphoma</condition>
  <condition>Noncontiguous Stage II Grade 2 Follicular Lymphoma</condition>
  <condition>Noncontiguous Stage II Grade 3 Follicular Lymphoma</condition>
  <condition>Noncontiguous Stage II Mantle Cell Lymphoma</condition>
  <condition>Noncontiguous Stage II Marginal Zone Lymphoma</condition>
  <condition>Noncontiguous Stage II Small Lymphocytic Lymphoma</condition>
  <condition>Paroxysmal Nocturnal Hemoglobinuria</condition>
  <condition>Previously Treated Myelodysplastic Syndromes</condition>
  <condition>Primary Myelofibrosis</condition>
  <condition>Recurrent Adult Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Adult Acute Myeloid Leukemia</condition>
  <condition>Recurrent Adult Burkitt Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Large Cell Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Mixed Cell Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Small Cleaved Cell Lymphoma</condition>
  <condition>Recurrent Adult Grade III Lymphomatoid Granulomatosis</condition>
  <condition>Recurrent Adult Hodgkin Lymphoma</condition>
  <condition>Recurrent Adult Immunoblastic Large Cell Lymphoma</condition>
  <condition>Recurrent Adult Lymphoblastic Lymphoma</condition>
  <condition>Recurrent Adult T-cell Leukemia/Lymphoma</condition>
  <condition>Recurrent Childhood Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Childhood Acute Myeloid Leukemia</condition>
  <condition>Recurrent Childhood Anaplastic Large Cell Lymphoma</condition>
  <condition>Recurrent Childhood Grade III Lymphomatoid Granulomatosis</condition>
  <condition>Recurrent Childhood Large Cell Lymphoma</condition>
  <condition>Recurrent Childhood Lymphoblastic Lymphoma</condition>
  <condition>Recurrent Childhood Small Noncleaved Cell Lymphoma</condition>
  <condition>Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma</condition>
  <condition>Recurrent Grade 1 Follicular Lymphoma</condition>
  <condition>Recurrent Grade 2 Follicular Lymphoma</condition>
  <condition>Recurrent Grade 3 Follicular Lymphoma</condition>
  <condition>Recurrent Mantle Cell Lymphoma</condition>
  <condition>Recurrent Marginal Zone Lymphoma</condition>
  <condition>Recurrent Mycosis Fungoides/Sezary Syndrome</condition>
  <condition>Recurrent Small Lymphocytic Lymphoma</condition>
  <condition>Recurrent/Refractory Childhood Hodgkin Lymphoma</condition>
  <condition>Refractory Chronic Lymphocytic Leukemia</condition>
  <condition>Refractory Multiple Myeloma</condition>
  <condition>Relapsing Chronic Myelogenous Leukemia</condition>
  <condition>Secondary Acute Myeloid Leukemia</condition>
  <condition>Secondary Myelodysplastic Syndromes</condition>
  <condition>Splenic Marginal Zone Lymphoma</condition>
  <condition>Stage III Adult Diffuse Small Cleaved Cell Lymphoma</condition>
  <condition>Stage III Adult Immunoblastic Large Cell Lymphoma</condition>
  <condition>Stage III Adult Lymphoblastic Lymphoma</condition>
  <condition>Stage III Grade 1 Follicular Lymphoma</condition>
  <condition>Stage III Grade 2 Follicular Lymphoma</condition>
  <condition>Stage III Grade 3 Follicular Lymphoma</condition>
  <condition>Stage III Mantle Cell Lymphoma</condition>
  <condition>Stage III Marginal Zone Lymphoma</condition>
  <condition>Stage III Small Lymphocytic Lymphoma</condition>
  <condition>Stage IV Adult Burkitt Lymphoma</condition>
  <condition>Stage IV Adult Diffuse Small Cleaved Cell Lymphoma</condition>
  <condition>Stage IV Adult Immunoblastic Large Cell Lymphoma</condition>
  <condition>Stage IV Adult Lymphoblastic Lymphoma</condition>
  <condition>Stage IV Grade 1 Follicular Lymphoma</condition>
  <condition>Stage IV Grade 2 Follicular Lymphoma</condition>
  <condition>Stage IV Grade 3 Follicular Lymphoma</condition>
  <condition>Stage IV Mantle Cell Lymphoma</condition>
  <condition>Stage IV Marginal Zone Lymphoma</condition>
  <condition>Stage IV Small Lymphocytic Lymphoma</condition>
  <condition>Waldenstr√∂m Macroglobulinemia</condition>
  <arm_group>
    <arm_group_label>Treatment (Reduced intensity allogeneic stem cell transplant)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan* IV over 30 minutes on day -2. Patients then undergo total-body irradiation on day -1 and allogeneic stem cell transplantation on day 0.
Note: *Patients with chromosomal breakage syndromes, such as Fanconi anemia or dyskeratosis congenita, receive anti-thymocyte globulin IV over 4 hours on day -4 to -2 instead of melphalan.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (Reduced intensity allogeneic stem cell transplant)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (Reduced intensity allogeneic stem cell transplant)</arm_group_label>
    <other_name>Alkeran</other_name>
    <other_name>CB-3025</other_name>
    <other_name>L-PAM</other_name>
    <other_name>L-phenylalanine mustard</other_name>
    <other_name>L-Sarcolysin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>total-body irradiation</intervention_name>
    <description>Undergo total-body irradiation</description>
    <arm_group_label>Treatment (Reduced intensity allogeneic stem cell transplant)</arm_group_label>
    <other_name>TBI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic hematopoietic stem cell transplantation</intervention_name>
    <description>Undergo allogeneic stem cell transplantation</description>
    <arm_group_label>Treatment (Reduced intensity allogeneic stem cell transplant)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (Reduced intensity allogeneic stem cell transplant)</arm_group_label>
    <other_name>ATG</other_name>
    <other_name>ATGAM</other_name>
    <other_name>lymphocyte immune globulin</other_name>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of a histology documented hematologic malignancy or marrow disorder

          -  Bone marrow failure disorders and other non-malignant hematologic or immunologic
             disorders:

               -  Acquired bone marrow failure disorders include aplastic anemia, paroxysmal
                  nocturnal hemoglobinuria (PNH):

                    -  Primary allogeneic hematopoietic stem cell transplantation (HSCT) is
                       appropriate for selected patients with severe aplastic anemia; however,
                       patients with aplastic anemia must have failed at least one cycle of
                       standard immunosuppressive therapy with calcineurin inhibitor plus
                       anti-thymocyte globulin (ATG) if a fully-matched donor is not available

                    -  Patients with PNH must have a history of thrombosis related to PNH

               -  Hereditary bone marrow failure disorders include Fanconi anemia or related
                  chromosomal breakage syndrome dyskeratosis congenita, Diamond-Blackfan anemia,
                  Shwachman-Diamond syndrome, Kostmann syndrome, congenital amegakaryocytic
                  thrombocytopenia:

                    -  Fanconi anemia or related chromosomal breakage syndrome: positive chromosome
                       breakage analysis using diepoxybutane (DEB) or mitomycin C if applicable

                    -  Dyskeratosis: diagnosis is supported by using either telomerase reverse
                       transcriptase (TERC) gene mutation in autosomal dominant Dyskeratosis
                       Congenita or Xlinked DKC1 gene mutation

               -  Other non-malignant hematologic or immunologic disorders that require
                  transplantation

                    -  Quantitative or qualitative congenital platelet disorders (including but not
                       limited to congenital amegakaryocytopenia, absent-radii syndrome,
                       Glanzmann's thrombasthenia)

                    -  Quantitative or qualitative congenital neutrophil disorders (including but
                       not limited to chronic granulomatous disease, congenital neutropenia)

                    -  Congenital primary immunodeficiencies (including but not limited to Severe
                       Combined Immunodeficiency Syndrome, Wiskott-Aldrick syndrome, CD40 ligand
                       deficiency, T-cell deficiencies)

          -  Acute leukemias:

               -  Subjects must be ineligible for conventional myeloablative transplantation;

               -  Resistant or recurrent disease after at least one standard combination
                  chemotherapy regime or first remission patients at high risk of relapse OR First
                  remission patients at high risk of relapse:

               -  Acute myeloid leukemia (AML)- antecedent myelodysplastic syndrome, secondary AML,
                  high risk cytogenetic abnormalities or normal cytogenetics with high-risk
                  molecular features (e.g. Flt3-ITD mutation, mixed-lineage leukemia [MLL],
                  wildtype NPM1);

               -  Acute lymphocytic leukemia (ALL)- high or standard risk ALL

          -  Chronic Myeloid Leukemia (CML):

               -  Chronic phase (intolerant or unresponsive to imatinib and/or other tyrosine
                  kinase inhibitors), second chronic phase or accelerated phase who are ineligible
                  for conventional myeloablative transplantation

          -  Myeloproliferative and myelodysplastic syndromes (MDS):

               -  Myelofibrosis (with/without splenectomy) with intermediate to high risk features

               -  Advanced polycythemia vera not responding to standard therapy

               -  MDS with an international prostate symptom score (IPSS) score of Int-2 or higher

               -  MDS with lower IPSS scores Int-1 or less with severe clinical features such as
                  severe neutropenia or thrombocytopenia or high risk chromosome abnormalities such
                  as monosomy 7

               -  Secondary massively parallel signature sequencing (MPSS) with any IPSS scores

               -  Chronic myelomoncytic leukemia

          -  Lymphoproliferative disease:

               -  Chronic lymphocytic leukemia (CLL), low-grade non-Hodgkin lymphoma (NHL)
                  (recurrent or persistent) fludarabine refractory or with less than 6 months
                  duration of complete response (CR) between courses of conventional therapy

               -  Multiple myeloma, progressive disease after autologous stem cell transplant or as
                  planned tandem (allogeneic transplant after prior autologous stem cell
                  transplant)

               -  Waldenstroms macroglobulinemia (failed one standard regimen)

               -  High grade NHL and diffuse large B-cell lymphoma (DLBCL)

               -  Not eligible for conventional myeloablative HSCT OR failed autologous HSCT

               -  First remission lymphoblastic lymphoma, or small, non-cleaved cell lymphoma or
                  mantle cell lymphoma

          -  Hodgkin disease:

               -  Relapsed or refractory after front-line therapy

               -  Failed or were not eligible for autologous transplantation

          -  Failed prior autotransplant

          -  Age &gt;= 3 and =&lt; 75 years for blood and bone marrow transplants and age &gt;= 3, &lt; 60 for
             cord blood transplants

          -  No serious uncontrolled psychiatric illness

          -  No concomitant active malignancy other than non-melanoma skin cancer

          -  Non-pregnant and non-nursing women (women or men with reproductive potential should
             agree to use an effective means of birth control)

          -  Patients may have received prior autologous bone marrow transplant (BMT) or prior
             myeloablative allogeneic BMT (at least 60 days have elapsed)

          -  At least 2 weeks since prior chemotherapy, radiation treatment and/or surgery

          -  Informed consent

          -  DONOR: Permissible HLA matching: Related donors- single antigen mismatch at HLA A, B
             or DRB 1; unrelated donors- a single antigen mismatch at HLA A, B, or C, +/-
             additional single allele level mismatch at A, B, C or DRB1; cord blood &gt;= 4 out of 6
             antigen match at HLA A, B, DRB1)

          -  DONOR: Compatibility at the four most informative HLA loci: A, B, C and DRB1 are
             important for reducing the risk of GVHD and successful transplant outcomes; the A, B,
             C and DRB1 loci comprise 8 possible alleles (a haplotype being inherited from each
             parent); one additional locus, HLA-DQ, is also typed to ascertain haplotypes and
             assist in the search for a compatible donor; however mismatching at DQ has not been
             shown to be associated with adverse outcomes; high resolution molecular typing (at the
             allele level) is now the standard of care for unrelated donor searches and allows
             greater refinement of the search strategy

          -  DONOR: Matched related donor: a single antigen mismatch at A, B, or the DR transplant
             from a family member is associated with a higher risk of GVHD but similar overall
             survival when compared to full identity at these 3 regions; related donor/recipient
             pairs must be matched at 5 of 6 HLA antigens (A, B, DRBl)

          -  DONOR: Unrelated donor: when evaluating patients for unrelated donor transplant, a
             higher degree of matching is preferred due to minimize the risk of GVHD; the A, B, C,
             DRB1 and DQ loci, comprising 10 possible alleles, will be typed routinely for all
             unrelated transplants; given the higher risk of TRM in mismatched transplants, RIT is
             often the best way to mitigate the risk; evolving data from the National Marrow Donor
             Program now makes it possible to estimate the risks of donor-recipient HLA mismatch at
             the allele or antigen level; the higher risk from HLA-mismatching must be carefully
             assessed with respect to the clinical urgency and the patient's risk by the transplant
             physician; antigen level mismatches at DQ are inconsequential to transplant outcomes
             and are ignored with respect to donor selection for the purposes of this protocol,
             with matching requirements confined to the 8 loci involving HLA A, B, C and DRB1; for
             the purpose of this protocol, a single antigen mismatch at HLA A, B, or C, with or
             without additional single allele level mismatch may participate in this protocol for
             voluntary unrelated donors (blood or marrow); patients must be at least antigen-level
             matched at DRB1

          -  DONOR: If a patient has no suitable family donor matched for 5 of 6 HLA antigens (A,
             B, DRB1) and no suitable unrelated donor is identified or for reasons of urgency, the
             patient can be considered a candidate for cord blood transplant, provided a cord blood
             donor is identified with a &gt;= 4 out of 6 antigen match at HLA A, B, DRB1 antigens; the
             cord blood product must provide a minimum of 2 x 10^7 nucleated cells/kg, test
             negative for HIV and Hepatitis A, Band C, and sterility assays have no growth; the
             cord blood products are located through the National Marrow Donor Program, the
             American Registry, or the Bone Marrow Donor Worldwide or other established registries,
             and may be stored in the N.Y Placental Cord Blood Bank, the St. Louis Cord Blood Bank,
             or any of the established, registered International blood and marrow banks

          -  DONOR: Donor must be healthy and have nonreactive test results for all infectious
             disease assays as required by state and federal regulations; donors who screen
             seropositive for hepatitis and/or syphilis must be cleared by infectious disease
             consultation

          -  DONOR: The donor must have no uncontrolled cardiopulmonary, renal, endocrine, hepatic
             or psychiatric disease to render donation unsafe

          -  DONOR: The donor must be able to give informed consent for peripheral blood stem cell
             collection or bone marrow collection

          -  DONOR: Syngeneic donors are not eligible

          -  DONOR: Donors who have poor peripheral venous access, may require central venous line
             placement for stem cell apheresis

        Exclusion Criteria:

          -  Uncontrolled central nervous system (CNS) disease (for hematologic malignancies)

          -  Karnofsky (adult) or Lansky (for =&lt; 16 years) performance status =&lt; 50%

          -  Diffusing capacity of the lung for carbon monoxide (DLCO) less than 40% predicted,
             corrected for hemoglobin (Hb) and/or alveolar ventilation

          -  Cardiac: left ventricular ejection fraction less than 40%

          -  Bilirubin &gt;= 3 x upper limit of normal

          -  Liver alkaline phosphatase &gt;= 3 x upper limit of normal

          -  Serum glutamic oxaloacetic transaminase (SGOT) or serum glutamic pyruvate transaminase
             (SGPT) &gt;= 3 x upper limit of normal

          -  Child's class B and C liver failure

          -  Calculated creatinine clearance &lt; 40 cc/min by the modified Cockcroft-Gault formula
             for adults or the Schwartz formula for pediatrics

          -  Patients who have received maximally allowed doses (given in 2 Gy fractions, or
             equivalent) of previous radiation therapy to various organs as follows:

               -  Mediastinum 40 Gy

               -  Heart (any volume) 36 Gy

               -  Whole lungs 12 Gy

               -  Small bowel (any volume) 46 Gy

               -  Kidneys 12 Gy

               -  Whole liver 20 Gy

               -  Spinal cord (any volume) 36 Gy

               -  Whole brain 30 Gy Enrollment of patients who previously receive higher than
                  allowed dose of radiation to a small volume of lungs, liver, and brain will be
                  determine by the discretion of the radiation oncologist on the study

          -  Uncontrolled diabetes mellitus, cardiovascular disease, active serious infection or
             other condition which, in the opinion of treating physician, would make this protocol
             unreasonably hazardous for the patient

          -  Human immunodeficiency virus (HIV) positive

          -  Patients who in the opinion of the treating physician are unlikely to comply with the
             restrictions of allogeneic stem cell transplantation based on formal psychosocial
             screening

          -  Females of childbearing potential with a positive pregnancy test
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Chen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2009</study_first_submitted>
  <study_first_submitted_qc>March 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2009</study_first_posted>
  <results_first_submitted>May 5, 2016</results_first_submitted>
  <results_first_submitted_qc>May 5, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 13, 2016</results_first_posted>
  <last_update_submitted>November 29, 2017</last_update_submitted>
  <last_update_submitted_qc>November 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Burkitt Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Immunoblastic</mesh_term>
    <mesh_term>Plasmablastic Lymphoma</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Mycosis Fungoides</mesh_term>
    <mesh_term>Sezary Syndrome</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
    <mesh_term>Leukemia, T-Cell</mesh_term>
    <mesh_term>Leukemia-Lymphoma, Adult T-Cell</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
    <mesh_term>Lymphomatoid Granulomatosis</mesh_term>
    <mesh_term>Lymphoma, Extranodal NK-T-Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid, Accelerated Phase</mesh_term>
    <mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative</mesh_term>
    <mesh_term>Hypereosinophilic Syndrome</mesh_term>
    <mesh_term>Fanconi Anemia</mesh_term>
    <mesh_term>Fanconi Syndrome</mesh_term>
    <mesh_term>Hemoglobinuria</mesh_term>
    <mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
    <mesh_term>Leukemia, Neutrophilic, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Reduced Intensity Allogeneic Stem Cell Transplant)</title>
          <description>Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan* IV over 30 minutes on day -2. Patients then undergo total-body irradiation on day -1 and allogeneic stem cell transplantation on day 0.
Note: *Patients with chromosomal breakage syndromes, such as Fanconi anemia or dyskeratosis congenita, receive anti-thymocyte globulin IV over 4 hours on day -4 to -2 instead of melphalan.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Reduced Intensity Allogeneic Stem Cell Transplant)</title>
          <description>Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan* IV over 30 minutes on day -2. Patients then undergo total-body irradiation on day -1 and allogeneic stem cell transplantation on day 0.
Note: *Patients with chromosomal breakage syndromes, such as Fanconi anemia or dyskeratosis congenita, receive anti-thymocyte globulin IV over 4 hours on day -4 to -2 instead of melphalan.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="62"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.6" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Day 100 TRM</title>
        <description>Day 100 Treatment Related Mortality An exact 95% confidence interval will be provided.</description>
        <time_frame>First 100 days</time_frame>
        <population>All treated and eligible patients</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Reduced Intensity Allogeneic Stem Cell Transplant)</title>
            <description>Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan* IV over 30 minutes on day -2. Patients then undergo total-body irradiation on day -1 and allogeneic stem cell transplantation on day 0.
Note: *Patients with chromosomal breakage syndromes, such as Fanconi anemia or dyskeratosis congenita, receive anti-thymocyte globulin IV over 4 hours on day -4 to -2 instead of melphalan.</description>
          </group>
        </group_list>
        <measure>
          <title>Day 100 TRM</title>
          <description>Day 100 Treatment Related Mortality An exact 95% confidence interval will be provided.</description>
          <population>All treated and eligible patients</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.44" lower_limit="3.08" upper_limit="17.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to ANC Engraftment</title>
        <description>Median Time to ANC Engraftment
Summarized using standard descriptive statistics along with corresponding 95% confidence intervals.</description>
        <time_frame>Days 30</time_frame>
        <population>All treated and eligible patients</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Reduced Intensity Allogeneic Stem Cell Transplant)</title>
            <description>Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan* IV over 30 minutes on day -2. Patients then undergo total-body irradiation on day -1 and allogeneic stem cell transplantation on day 0.
Note: *Patients with chromosomal breakage syndromes, such as Fanconi anemia or dyskeratosis congenita, receive anti-thymocyte globulin IV over 4 hours on day -4 to -2 instead of melphalan.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to ANC Engraftment</title>
          <description>Median Time to ANC Engraftment
Summarized using standard descriptive statistics along with corresponding 95% confidence intervals.</description>
          <population>All treated and eligible patients</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5" lower_limit="0" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to Platelet Engraftment</title>
        <description>Median Time to Platelet Engraftment
Summarized using standard descriptive statistics along with corresponding 95% confidence intervals.</description>
        <time_frame>Day 100</time_frame>
        <population>All treated and eligible patients</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Reduced Intensity Allogeneic Stem Cell Transplant)</title>
            <description>Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan* IV over 30 minutes on day -2. Patients then undergo total-body irradiation on day -1 and allogeneic stem cell transplantation on day 0.
Note: *Patients with chromosomal breakage syndromes, such as Fanconi anemia or dyskeratosis congenita, receive anti-thymocyte globulin IV over 4 hours on day -4 to -2 instead of melphalan.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Platelet Engraftment</title>
          <description>Median Time to Platelet Engraftment
Summarized using standard descriptive statistics along with corresponding 95% confidence intervals.</description>
          <population>All treated and eligible patients</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.0" lower_limit="0" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Complete Donor Chimerism - Blood</title>
        <description>Rate of Complete Donor Chimerism - Blood
Summarized using standard descriptive statistics.</description>
        <time_frame>Day 30</time_frame>
        <population>All treated and eligible patients, who were able to complete testing</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Reduced Intensity Allogeneic Stem Cell Transplant)</title>
            <description>Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan* IV over 30 minutes on day -2. Patients then undergo total-body irradiation on day -1 and allogeneic stem cell transplantation on day 0.
Note: *Patients with chromosomal breakage syndromes, such as Fanconi anemia or dyskeratosis congenita, receive anti-thymocyte globulin IV over 4 hours on day -4 to -2 instead of melphalan.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Complete Donor Chimerism - Blood</title>
          <description>Rate of Complete Donor Chimerism - Blood
Summarized using standard descriptive statistics.</description>
          <population>All treated and eligible patients, who were able to complete testing</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Complete Donor Chimerism - Blood</title>
        <description>Rate of Complete Donor Chimerism - Blood
Summarized using standard descriptive statistics.</description>
        <time_frame>Day 100</time_frame>
        <population>All treated and eligible patients, who were able to complete testing</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Reduced Intensity Allogeneic Stem Cell Transplant)</title>
            <description>Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan* IV over 30 minutes on day -2. Patients then undergo total-body irradiation on day -1 and allogeneic stem cell transplantation on day 0.
Note: *Patients with chromosomal breakage syndromes, such as Fanconi anemia or dyskeratosis congenita, receive anti-thymocyte globulin IV over 4 hours on day -4 to -2 instead of melphalan.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Complete Donor Chimerism - Blood</title>
          <description>Rate of Complete Donor Chimerism - Blood
Summarized using standard descriptive statistics.</description>
          <population>All treated and eligible patients, who were able to complete testing</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute GVHD Grade III-IV</title>
        <description>Acute GVHD grade III-IV
Summarized using standard descriptive statistics along with corresponding 95% confidence intervals.</description>
        <time_frame>Up to day 100</time_frame>
        <population>All treated and eligible patients</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Reduced Intensity Allogeneic Stem Cell Transplant)</title>
            <description>Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan* IV over 30 minutes on day -2. Patients then undergo total-body irradiation on day -1 and allogeneic stem cell transplantation on day 0.
Note: *Patients with chromosomal breakage syndromes, such as Fanconi anemia or dyskeratosis congenita, receive anti-thymocyte globulin IV over 4 hours on day -4 to -2 instead of melphalan.</description>
          </group>
        </group_list>
        <measure>
          <title>Acute GVHD Grade III-IV</title>
          <description>Acute GVHD grade III-IV
Summarized using standard descriptive statistics along with corresponding 95% confidence intervals.</description>
          <population>All treated and eligible patients</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" lower_limit="16" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>1 yr Extenstive Chronic GVHD</title>
        <description>1 yr Extensive Chronic GVHD
Summarized using standard descriptive statistics along with corresponding 95% confidence intervals.</description>
        <time_frame>Up to 4.5 years</time_frame>
        <population>All treated and eligible who survived to day 100 and were eligible to get chronic GVHD</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Reduced Intensity Allogeneic Stem Cell Transplant)</title>
            <description>Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan* IV over 30 minutes on day -2. Patients then undergo total-body irradiation on day -1 and allogeneic stem cell transplantation on day 0.
Note: *Patients with chromosomal breakage syndromes, such as Fanconi anemia or dyskeratosis congenita, receive anti-thymocyte globulin IV over 4 hours on day -4 to -2 instead of melphalan.</description>
          </group>
        </group_list>
        <measure>
          <title>1 yr Extenstive Chronic GVHD</title>
          <description>1 yr Extensive Chronic GVHD
Summarized using standard descriptive statistics along with corresponding 95% confidence intervals.</description>
          <population>All treated and eligible who survived to day 100 and were eligible to get chronic GVHD</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" lower_limit="45" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>3 yr Overall Survival</title>
        <description>3 yr Overall Survival estimated using the Kaplan-Meier method.</description>
        <time_frame>Up to 4.5 years</time_frame>
        <population>All treated and eligible patients</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Reduced Intensity Allogeneic Stem Cell Transplant)</title>
            <description>Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan* IV over 30 minutes on day -2. Patients then undergo total-body irradiation on day -1 and allogeneic stem cell transplantation on day 0.
Note: *Patients with chromosomal breakage syndromes, such as Fanconi anemia or dyskeratosis congenita, receive anti-thymocyte globulin IV over 4 hours on day -4 to -2 instead of melphalan.
fludarabine phosphate: Given IV
melphalan: Given IV
total-body irradiation: Undergo total-body irradiation
allogeneic hematopoietic stem cell transplantation: Undergo allogeneic stem cell transplantation
anti-thymocyte globulin: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>3 yr Overall Survival</title>
          <description>3 yr Overall Survival estimated using the Kaplan-Meier method.</description>
          <population>All treated and eligible patients</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.0" lower_limit="33.0" upper_limit="57.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Reduced Intensity Allogeneic Stem Cell Transplant)</title>
          <description>Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan* IV over 30 minutes on day -2. Patients then undergo total-body irradiation on day -1 and allogeneic stem cell transplantation on day 0.
Note: *Patients with chromosomal breakage syndromes, such as Fanconi anemia or dyskeratosis congenita, receive anti-thymocyte globulin IV over 4 hours on day -4 to -2 instead of melphalan.
fludarabine phosphate: Given IV
melphalan: Given IV
total-body irradiation: Undergo total-body irradiation
allogeneic hematopoietic stem cell transplantation: Undergo allogeneic stem cell transplantation
anti-thymocyte globulin: Given IV</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Graft versus host disease</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Anuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Urinary tract disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hospitalisation</sub_title>
                <counts group_id="E1" events="16" subjects_affected="12" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Administrator, Compliance - Clinical Research Services</name_or_title>
      <organization>Roswell Park Cancer Institute</organization>
      <phone>716-845-2300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

